CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Itraconazole (Sporanox) oral capsules prior authorization

Defines prior authorization coverage criteria for itraconazole (Sporanox) oral capsules for treatment and prophylaxis of specified fungal infections for members of the payer.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyItraconazole (Sporanox) oral capsules prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization with documentation showing indication and, for onychomycosis, a confirming fungal diagnostic test (KOH, culture, or nail biopsy).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

multipleFDA-listed indications

extensiveCompendial uses

PA requiredCoverage stance

diagnostic requiredOnychomycosis testing

Coverage Criteria for Itraconazole (Sporanox) Capsules

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Group A: Superficial/mucocutaneous fungal infections: Pityriasis versicolor or Tinea versicolor; Onychomycosis (tinea unguium) due to dermatophytes confirmed by a fungal diagnostic test (potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy).

Diagnostic confirmation required for onychomycosis.

Group B: Serious/systemic infections and prophylaxis: Disseminated histoplasmosis; Central nervous system (CNS) histoplasmosis; Histoplasmosis prophylaxis in HIV infection; Coccidioidomycosis prophylaxis in HIV infection; Invasive fungal infection prophylaxis in patients with chronic granulomatous disease; Primary therapy for chronic cavitary pulmonary aspergillosis; Blastomycosis; Histoplasmosis; Primary therapy for allergic bronchopulmonary aspergillosis (in combination with systemic corticosteroids); Aspergillosis in patients intolerant of or refractory to amphotericin B; Coccidioidomycosis; Cryptococcosis; Sporotrichosis; Talaromycosis (formerly Penicilliosis); Microsporidiosis; Invasive fungal infection prophylaxis in liver transplant patients; Invasive fungal infection prophylaxis in patients with hematologic malignancy.

Includes multiple compendial and FDA indications.

Group C: Dermatophyte skin infections: Tinea corporis; Tinea cruris; Tinea capitis; Tinea manuum; Tinea pedis.

Listed as covered indications.

Prior therapy / Alternative-agent requirement: Patient experienced inadequate treatment response, intolerance, or has a contraindication to fluconazole, griseofulvin, or terbinafine.

Policy lists alternative-agent failure/intolerance as a criterion for coverage in some situations.

Provider Actions, Authorization, and Documentation Requirements

Prior Authorization

Coverage with prior authorization

Coverage with prior authorization — Itraconazole (Sporanox capsules) will be covered with prior authorization when the request is for listed FDA‑approved or compendial indications such as onychomycosis (toenail or fingernail) confirmed by a fungal diagnostic test (KOH preparation, fungal culture, or nail biopsy), blastomycosis, histoplasmosis (including chronic cavitary pulmonary disease and disseminated non‑meningeal disease), aspergillosis in patients intolerant or refractory to amphotericin B, and other invasive or prophylactic fungal indications described in the policy. Requests must meet the specific clinical criteria outlined for the requested indication.

Denial Risk

Prior authorization required

Prior authorization requirement — All requests for itraconazole (Sporanox capsules) require prior authorization. Requests that do not meet the coverage criteria and documentation requirements described in this section are subject to denial.

Documentation Required

Diagnostic confirmation required for onychomycosis

Diagnostic documentation for onychomycosis — For onychomycosis, appropriate nail specimens must be obtained and documented prior to initiating therapy (or contemporaneously if therapy is started empirically). Acceptable diagnostic tests include potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy to confirm dermatophyte infection.

Step Therapy

Alternative therapy requirement

Alternative therapy requirement — Coverage may require a prior trial of, intolerance to, or contraindication to alternative antifungal agents (for example fluconazole, griseofulvin, terbinafine) when clinically appropriate before approving itraconazole for certain indications; document prior treatments, reasons for discontinuation, or contraindications in the prior authorization request.

Background and Drug Information

Itraconazole is an oral azole antifungal indicated for multiple systemic and superficial fungal infections, including blastomycosis, histoplasmosis, aspergillosis, and onychomycosis; specimens for culture or other laboratory studies are recommended prior to therapy initiation though treatment may begin empirically.

For nail infections (onychomycosis), the policy requires diagnostic confirmation prior to initiating itraconazole — confirmation by potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy is specified as the preferred documentation to support therapy.

Definitions and Diagnostic Criteria

Onychomycosis diagnostic confirmation — required tests and timing

Required diagnostic testsConfirmation of onychomycosis by potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy before initiating itraconazole therapy.

When to obtain specimensAppropriate nail specimens should be obtained prior to initiating treatment, though therapy may begin empirically pending results.

Purpose of testingLaboratory testing is used to isolate and identify causative organisms to guide and adjust antifungal therapy once results are available.

Covered condition specifiedOnychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium).